Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
暂无分享,去创建一个
H. Kantarjian | G. Garcia-Manero | J. Maciejewski | S. Verstovsek | X. Su | K. Patel | N. Daver | C. Dinardo | Wencai Ma | C. Bueso-Ramos | M. Sekeres | Andrew L Sochacki | A. Nazha | S. Loghavi | R. Komrokji | A. Shaver | M. Savona | S. Pierce | P. Bose | Najla Al-Ali | A. Sochacki
[1] A. Tefferi,et al. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management , 2018, American journal of hematology.
[2] W. Hogan,et al. Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience , 2018, Leukemia & lymphoma.
[3] Z. Estrov,et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms , 2018, American journal of hematology.
[4] J. Teruya-Feldstein,et al. JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition , 2018, The Journal of clinical investigation.
[5] Delong Liu,et al. SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome , 2017, Biomarker Research.
[6] Anthony Stein,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[7] A. Tefferi,et al. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS‐T): 2017 update on diagnosis, risk‐stratification, and management , 2017, American journal of hematology.
[8] J. Maciejewski,et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2016, Leukemia.
[9] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[10] F. Stingo,et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. , 2014, Blood.
[11] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[12] H. Kantarjian,et al. Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy , 2014, Leukemia.
[13] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[14] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[15] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[16] C Haferlach,et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations , 2013, Leukemia.
[17] D. Birnbaum,et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias , 2013, Leukemia.
[18] Roberta Spinelli,et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia , 2012, Nature Genetics.
[19] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[20] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[22] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[23] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[24] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.